1/12
Cipla: Mumbai-based pharmaceutical and biotechnology company Cipla has sought approval from the Indian regulators to launch experimental Covid-19 drug favipiravir in India for treatment of coronavirus patients.
In This Pic : cipla
Pic Courtesy : BCCL
Read More
2/12
Under the auspices of Indian Council of Medical Research (ICMR), Cipla will conduct a limited trial prior to marketing the product as Ciplenza.
In This Pic : cipla
Pic Courtesy : Reuters
Read More
3/12
Zydus Cadila: Ahmedabad-based Zydus Cadila has launched a research program to develop a vaccine for Covid-19.
In This Pic : Zydus Cadila
Pic Courtesy : BCCL
Read More
4/12
The Indian drugmaker will launch a two-pronged approach, with a team at the Vaccine Technology Center in India and another at its research arm in Europe, Etna Biotech, working on the project.
In This Pic : Zydus Cadila
Pic Courtesy : BCCL
Read More
5/12
Serum India Institute: Pune-based Serum Institute of India (SII) made headlines after it launched three initiatives for conquering coronavirus - one with US-based biotech company Codagenix, another with UK's Oxford University and one with its own recombinant BCG vaccine.
In This Pic : Serum India Institute
Pic Courtesy : AP
Read More
खबरें एक झलक में :
ऐप पर देखें